On November 10, 2021 Enterome, a clinical stage biopharmaceutical company developing first-in-class immunomodulatory drugs based on its unique ability to decode the gut microbiome’s interaction with the immune system, reported that its CEO, Pierre Belichard, will present (in person) and participate at the Jefferies London Healthcare Conference in London, UK, which will take place November 16-19, 2021 (Press release, Enterome, NOV 10, 2021, View Source [SID1234595073]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Presentation details
Enterome Presentation (in person) – Wednesday November 17, 2021 at 2:25 pm GMT
Webcast: View Source
The presentation will be webcast live and archived for 30 days thereafter.
Enterome’s CEO, Pierre Belichard, will provide an overview of the Company and the progress it has made with its advanced OncoMimics pipeline of transformational medicines for cancer as well as its other fully owned EndoMimics pipeline for immune diseases.
Enterome’s most advanced OncoMimics drug candidates are:
EO2401, a therapeutic cancer vaccine candidate currently in clinical development for recurrent glioblastoma and adrenal tumors. EO2401 has already shown strong immunogenicity data in brain and adrenal cancer patients with clinical proof of concept data expected in H1 2022, and
EO2463, a second OncoMimic cancer vaccine, in clinical development for the treatment of indolent non-Hodgkin lymphoma with clinical proof of concept data planned for H1 2023
In addition, the Company’s most advanced EndoMimics candidate is:
EB1010, a new orally delivered bioactive and a potent local inducer of IL-10, which has been selected to provide improved therapeutic outcomes for patients with inflammatory bowel disease (IBD). EB1010 is expected to enter clinical trial in 2023